MARVELD1 Activators
MARVELD1 Activators encompass a variety of chemical compounds that indirectly enhance the functional activity of MARVELD1, prominently involved in cell-cell adhesion and maintaining epithelial barrier integrity. Phorbol 12-myristate 13-acetate (PMA) and 1,2-Dioctanoyl-sn-glycerol (DiC8) exert their effects by activating protein kinase C (PKC), a key regulator in tight junction assembly, which is a cellular process where MARVELD1 plays a critical role. Forskolin and 8-Bromo-cyclic AMP, both elevate intracellular cyclic AMP levels, leading to PKA activation. PKA is known to influence cellular junctions and the cytoskeletal organization, thereby potentially enhancing the function of MARVELD1. Similarly, the calcium ionophore A23187 increases intracellular calcium levels, triggering calcium-dependent signaling pathways that can support the activity of MARVELD1 in tight junction formation. Y-27632, as a ROCK inhibitor, and NSC 23766, as a Rac1 inhibitor, provide an indirect enhancement of MARVELD1 by modulating the actin cytoskeleton and cellular junctions.
Further, the activity of MARVELD1 is indirectly influenced by compounds that affect various kinases implicated in cell signaling. Epigallocatechin gallate (EGCG), as a kinase inhibitor, and Bisindolylmaleimide I (BIM I), as a PKC inhibitor, modulate competitive signaling pathways, which might favor MARVELD1-related activities. LY294002 and U0126, inhibitors of PI3K and MEK, respectively, can shift the balance of intracellular signaling to pathways that may involve MARVELD1 in the maintenance of membrane structures and tight junctions. SB203580, by inhibiting p38 MAPK, might enhance MARVELD1's involvement in stabilizing cellular junctions under stress conditions. Collectively, these chemical activators, through their targeted effects on different signaling molecules and pathways, facilitate an environment conducive to the enhanced activity of MARVELD1 without necessitating direct activation or upregulation of its expression. The orchestrated modulation of these pathways underscores the complex regulation of MARVELD1 and its pivotal role in epithelial barrier function and intercellular connectivity.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $40.00 $129.00 $210.00 $490.00 $929.00 | 119 | |
As a diacylglycerol analog, PMA activates protein kinase C (PKC), which could enhance MARVELD1 activity by promoting pathways involved in tight junction assembly and barrier function, processes where MARVELD1 is functionally relevant. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
By elevating cyclic AMP (cAMP) levels, Forskolin activates PKA, which can influence cellular junctions and cytoskeletal organization, thereby indirectly enhancing MARVELD1 activity in maintaining epithelial integrity. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $42.00 $72.00 $124.00 $238.00 $520.00 $1234.00 | 11 | |
EGCG inhibits multiple kinases, which might lead to reduced competitive signaling and thus indirectly promote MARVELD1-mediated pathways in cell-cell adhesion and barrier function. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
As a PI3K inhibitor, LY294002 modulates downstream Akt signaling, possibly favoring cellular processes that involve MARVELD1 in maintaining membrane structures and tight junctions. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
As a MEK inhibitor, U0126 may shift the equilibrium of intracellular signaling to enhance the role of MARVELD1 in cell-cell contact and barrier integrity through indirect effects on the ERK pathway. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
This inhibitor of p38 MAPK can influence cellular stress responses and cytokine signaling, potentially enhancing MARVELD1's role in cellular junction stabilization under stress conditions. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $54.00 $128.00 $199.00 $311.00 | 23 | |
By increasing intracellular calcium levels, A23187 activates calcium-dependent signaling pathways, which could indirectly support MARVELD1's function in tight junction assembly and epithelial barrier maintenance. | ||||||
1,2-Dioctanoyl-sn-glycerol | 60514-48-9 | sc-202397 sc-202397A | 10 mg 50 mg | $46.00 $249.00 | 2 | |
Mimicking diacylglycerol, DiC8 activates PKC, thereby potentially enhancing MARVELD1's role in cell-cell adhesion and tight junction organization. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $103.00 $237.00 | 36 | |
As a PKC inhibitor, BIM I may indirectly enhance MARVELD1 activity by modulating cellular pathways associated with tight junctions and epithelial barrier function, through its effects on PKC signaling. | ||||||
8-Bromo-cAMP | 76939-46-3 | sc-201564 sc-201564A | 10 mg 50 mg | $97.00 $224.00 | 30 | |
Analog of cAMP that activates PKA, potentially enhancing MARVELD1's involvement in pathways regulating cell morphology and tight junctions. | ||||||